Should I Buy UNCY? UNCY 2026 Analysis

Should You Buy Unicycive Therapeutics Inc (UNCY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

6.450

1 Day change

8.04%

52 Week Range

11.000

Analysis Updated At

2026/01/30

UNCY is not a good buy right now for an impatient investor. Despite a clear positive FDA catalyst (NDA acceptance with a June 2026 action date), the stock just sold off hard in the regular session (-10.49%) and is trading right on/just below near-term support (~6.05) with weakening momentum (MACD worsening). The setup is more “wait for stabilization and reclaim of key levels” than “buy immediately.”

Technical Analysis

Price/Trend: The stock dropped sharply during the regular session (-10.49%) and is only modestly higher post-market (+0.84%) around ~6.02. It’s sitting at a critical area: S1 ~6.054 (price is slightly below/around it), with the next support at S2 ~5.71. Resistance levels above are Pivot ~6.612, then R1 ~7.17. Momentum: MACD histogram is negative (-0.0228) and negatively expanding, signaling bearish momentum increasing. RSI: RSI_6 ~31, near oversold territory (not deeply oversold), which can support a short-term bounce attempt but does not confirm a reversal. Moving Averages: The MA stack is bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader structure had been constructive; however, the sudden selloff plus weakening MACD implies the short-term trend is damaged and needs confirmation (ideally a reclaim of ~6.61 pivot). Bottom line technically: Near-term is fragile; a bounce is possible from ~6.05/5.71 support, but the current tape is not showing confirmed upside follow-through.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Open interest is extremely call-heavy (OI put/call ~0.03; calls 319 vs puts 10), which reflects longer-standing bullish positioning/speculation. However, today’s volume put/call is 2.0 (puts > calls), even though total volume is tiny (9 contracts). That split suggests near-term hedging or bearish tactical positioning into/after the move. Implied volatility is extremely elevated (30D IV ~411.8%)—typical for biotech event-driven names—indicating the options market is pricing large swings. With IV this high, options pricing implies uncertainty rather than a clean bullish consensus.

Technical Summary

Sell

Buy

Positive Catalysts

FDA accepted the New Drug Application (NDA) for oxylanthanum carbonate; this is a meaningful regulatory milestone. A defined target action date in late June 2026 creates a clear, event-driven roadmap and can attract speculative interest ahead of the decision.
Hedge fund and insider activity are reported as neutral (no negative signal from notable selling pressure in the provided data).

Neutral/Negative Catalysts

Strong “sell-the-news” style reaction: the stock fell -10.49% during the regular session despite the positive FDA acceptance headlines, indicating weak immediate demand and/or profit-taking.
Regulatory catalyst timing is months away (June 2026 action date), which reduces urgency for immediate buying if the goal is quick upside.
Extremely high implied volatility signals large downside risk potential alongside upside, and today’s put-heavy volume ratio suggests short-term caution.

Financial Performance

Latest reported quarter: 2025/Q3. Revenue was 0 (no operating revenue reported). Net loss improved YoY to about -$6.01M (improvement of ~46.75% YoY), but EPS worsened to -0.33 (down ~28.26% YoY). Overall, this still reads like a pre-commercial biotech profile where the stock is driven more by regulatory events than by operating growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target change data was provided, so a recent trend in Wall Street ratings/targets cannot be confirmed from the dataset. With the available information, the pro case is event-driven upside from the FDA review path, while the con case is the market’s immediate negative price reaction and the long wait to the June 2026 decision.

5 Analyst Rating

Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is 35.8 USD with a low forecast of 21 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.970

Low

Averages

35.8

High

Current: 5.970

Low

Averages

35.8

High

H.C. Wainwright

NULL -> Buy

maintain

$9 -> $22

AI Analysis

2025-10-29

Reason

H.C. Wainwright

Price Target

$9 -> $22

AI Analysis

2025-10-29

maintain

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Unicycive Therapeutics to $22 from $9 and keeps a Buy rating on the shares. The believes the company's regulatory overhang has been revolved after its Type A meeting with the FDA. Unicycive plans to file a response to the complete response letter by year-end and expects a decision in the first half of 2026, the analyst tells investors in a research note.

Benchmark

Speculative Buy

maintain

$3 -> $21

2025-09-15

Reason

Benchmark

Price Target

$3 -> $21

2025-09-15

maintain

Speculative Buy

Reason

Benchmark raised the firm's price target on Unicycive Therapeutics to $21 from $3 and keeps a Speculative Buy rating on the shares, noting that the firm's new price target reflects a 1:10 reverse split and an updated discount rate after Unicycive said that it plans to complete a Type A meeting with the FDA to gain alignment on the best strategy to resolve the remaining issues outlined in the complete response letter for the oxylanthanum carbonate New Drug Application.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for UNCY

Unlock Now

UNCY Should I Buy

UNCY Should I Buy

Should You Buy Unicycive Therapeutics Inc (UNCY) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch